This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Posiphen
- DrugBank Accession Number
- DB15317
- Background
Posiphen is under investigation in clinical trial NCT02925650 (Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Posiphen (DB15317)
- Weight
- Average: 337.423
Monoisotopic: 337.179026993 - Chemical Formula
- C20H23N3O2
- Synonyms
- (+)-Posiphen
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcebutolol Posiphen may increase the bradycardic activities of Acebutolol. Acetylcholine The risk or severity of adverse effects can be increased when Posiphen is combined with Acetylcholine. Aclidinium Posiphen may increase the neuromuscular blocking activities of Aclidinium. Amantadine The therapeutic efficacy of Amantadine can be decreased when used in combination with Posiphen. Amifampridine The risk or severity of adverse effects can be increased when Posiphen is combined with Amifampridine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Z0O4TJ588O
- CAS number
- 116839-68-0
- InChI Key
- PBHFNBQPZCRWQP-AZUAARDMSA-N
- InChI
- InChI=1S/C20H23N3O2/c1-20-11-12-22(2)18(20)23(3)17-10-9-15(13-16(17)20)25-19(24)21-14-7-5-4-6-8-14/h4-10,13,18H,11-12H2,1-3H3,(H,21,24)/t18-,20+/m0/s1
- IUPAC Name
- (3aR,8aS)-1,3a,8-trimethyl-1H,2H,3H,3aH,8H,8aH-pyrrolo[2,3-b]indol-5-yl N-phenylcarbamate
- SMILES
- CN1CC[C@@]2(C)[C@@H]1N(C)C1=CC=C(OC(=O)NC3=CC=CC=C3)C=C21
References
- General References
- Not Available
- External Links
- ChemSpider
- 9424375
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Idiopathic Parkinson's Disease 1 somestatus stop reason just information to hide 2, 3 Completed Treatment Alzheimer's Disease (AD) 1 somestatus stop reason just information to hide 1 Terminated Treatment Alzheimer's Disease (AD) / Amnestic Mild Cognitive Impairment (aMCI) 1 somestatus stop reason just information to hide 1, 2 Completed Treatment Alzheimer's Disease (AD) 1 somestatus stop reason just information to hide 1, 2 Completed Treatment Alzheimer's Disease (AD) / Parkinson's Disease (PD) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0509 mg/mL ALOGPS logP 3.38 ALOGPS logP 4.25 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 12.86 Chemaxon pKa (Strongest Basic) 6.58 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 44.81 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 99.96 m3·mol-1 Chemaxon Polarizability 37.5 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0039000000-028baf5ce2c6d4fe262d Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-014i-0039000000-a660f08d65df024bc22e Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-1249000000-403b07c9acc3f19de818 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-001i-1091000000-949780f34ffce98cf448 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0v4j-9743000000-1f1be00517b978712482 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-02al-4981000000-aa13e4abd99d0e15b919 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 20, 2019 15:13 / Updated at June 12, 2020 16:53